Raymond James reiterates Scholar Rock stock Strong Buy on debt facility
#Raymond James #Scholar Rock #Strong Buy #Debt Financing #Blue Owl Capital #NASDAQ #Biotechnology
📌 Key Takeaways
- Raymond James maintained Strong Buy rating with $53 price target on Scholar Rock
- Scholar Rock secured $550 million debt facility with Blue Owl Capital
- Company has 26% stock gain over past six months, trading at $45.30
- Additional financing contingent on FDA approval and potential voucher monetization
📖 Full Retelling
Raymond James reiterated a Strong Buy rating and $53.00 price target on Scholar Rock (NASDAQ:SRRK) shares on March 3, 2026, following the biotechnology company's announcement of a new debt financing agreement with Blue Owl Capital. The financial institution maintained its optimistic outlook on the stock despite the company's ongoing losses, citing the new financing as a strategic move to support future growth initiatives. Scholar Rock, which specializes in neuromuscular and metabolic diseases, currently trades at $45.30 with a market capitalization of $4.64 billion, having gained 26% over the past six months. The debt facility, valued at up to $550 million, will provide crucial financial flexibility as the company advances its lead therapeutic candidate apitegromab through regulatory processes. Raymond James emphasized that Scholar Rock's liquid assets exceed short-term obligations with a current ratio of 6.3, supporting its ability to manage this transaction effectively. The financing structure includes $200 million available immediately, with an additional $150 million contingent upon FDA approval of apitegromab, and an optional $200 million at mutual consent. Management has also indicated potential monetization of a priority review voucher, estimated at approximately $200 million, which would further bolster the company's financial position and support commercialization efforts. This financial strategy comes on the heels of Scholar Rock's Q4 2025 earnings report, where the company posted an EPS of -$0.88, slightly exceeding analysts' expectations of -$0.90, representing a positive surprise of 2.22%.
🏷️ Themes
Financial Markets, Biotechnology, Corporate Finance
📚 Related People & Topics
Raymond James Financial
American multinational independent investment bank and financial services company
Raymond James Financial, Inc. is an American multinational independent investment bank and financial services company providing financial services to individuals, corporations, and municipalities through its subsidiary companies that engage primarily in investment and financial planning, in addition...
Blue Owl Capital
American alternative asset management firm
Blue Owl Capital Inc. is an American alternative investment asset management company that is listed on the New York Stock Exchange under the ticker symbol: "OWL". Headquartered in New York City, it has additional offices around the world, including London, Dubai, and Hong Kong.
Entity Intersection Graph
Connections for Raymond James Financial:
🏢
Wingstop
1 shared
🌐
Valuation
1 shared
🏢
American Tower
1 shared
🏢
Xponential Fitness
1 shared
🏢
Real estate investment trust
1 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil pares some gains, still hovering near multi-month highs on supply shock fears Stocks recover some of their losses, still deep in the red on Middle East conflict Gold slips on stronger dollar; safe haven demand remains strong amid Iran conflict JPMorgan names winner and loser sectors from Iran conflict (South Africa Philippines Nigeria) Raymond James reiterates Scholar Rock stock Strong Buy on debt facility By Analyst Ratings Published 03/03/2026, 02:21 PM Raymond James reiterates Scholar Rock stock Strong Buy on debt facility 0 SRRK 3.48% Investing.com - Raymond James reiterated a Strong Buy rating and $53.00 price target on Scholar Rock (NASDAQ:SRRK) shares following the company’s announcement of a new debt financing agreement. The stock currently trades at $45.30 with a market cap of $4.64 billion, having gained 26% over the past six months. The company announced a debt financing agreement with Blue Owl Capital for up to $550 million. Approximately $200 million will be utilized immediately, according to the firm. An InvestingPro Tip notes that Scholar Rock’s liquid assets exceed short-term obligations, with a current ratio of 6.3 supporting its financial flexibility for this transaction. An additional $150 million will be available upon FDA approval of apitegromab. The agreement also includes an optional $200 million at the mutual consent of Scholar Rock and Blue Owl. Management expressed openness to monetizing a priority review voucher in the event of marketing authorization for apitegromab. The firm estimates the voucher value at approximately $200 million. The additional liquidity would support commercial efforts for the company, according to Raymond James. For deeper insights into Scholar Rock’s financial health and comprehensive analysis, investors can access the company’s dedicated Pro Research Report, available exclusively on InvestingPro alongside reports for 1,400+ other US equities. In other r...
Read full article at source